Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Facilitated percutaneous coronary intervention: results from the SPEED trial
Autore:
Herrmann, HC; Li, RH; Ohman, EM;
Indirizzi:
Hosp Univ Penn, Philadelphia, PA 19104 USA Hosp Univ Penn Philadelphia PAUSA 19104 Penn, Philadelphia, PA 19104 USA Duke Univ, Cardiovasc Res Inst, Durham, NC USA Duke Univ Durham NC USADuke Univ, Cardiovasc Res Inst, Durham, NC USA
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: A, volume: 3, anno: 2001,
pagine: A26 - A34
SICI:
1520-765X(200105)3:A<A26:FPCIRF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; PRIMARY ANGIOPLASTY; THROMBOLYTIC THERAPY; RANDOMIZED TRIAL; IMMEDIATE ANGIOPLASTY; STENT IMPLANTATION; ARTERY DISEASE; REPERFUSION; ABCIXIMAB;
Keywords:
facilitated PCI; perfusion; acute MI; lytic; abciximab; SPEED;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Herrmann, HC Hosp Univ Penn, 3400 Spruce St,9 Founders Pavil, Philadelphia, PA 19104 USA Hosp Univ Penn 3400 Spruce St,9 Founders Pavil Philadelphia PA USA 19104
Citazione:
H.C. Herrmann et al., "Facilitated percutaneous coronary intervention: results from the SPEED trial", EUR H J SUP, 3(A), 2001, pp. A26-A34

Abstract

Facilitated percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) combines fibrinolytic therapy, glycoprotein (GP) IIb/IIIa receptor inhibition and early percutaneous intervention to optimize epicardial and microvascular reperfusion. Although fibrinolysis and primary angioplasty were once seen as competing therapies, new evidence indicates that they can be used together safely to improve outcomes. In addition, a new understanding of the role of platelets in acute MI has led to studies demonstrating the benefits of using GP IIb/IIIa receptor inhibitors in combination with fibrinolytic agents. The Thrombolysis in Myocardial Infarction (TIMI) 14and Strategies for Patency Enhancement in the Emergency Department (SPEED)trials have shown that combination therapy with reduced-dose alteplase or reteplase and full-dose abciximab improves TIMI grade 3 flow by an absoluteamount of 10-15% at 60 min, without a significant increase in bleeding. Inthe SPEED trial of abciximab used with or without low-dose fibrinolytic therapy, the addition of early facilitated PCI resulted in a core laboratory-assessed TIMI grade 3 flow rate of 85% and a normal mean corrected TIMI frame count while retaining the early benefit (between 30 and 60 min) of a pharmacological approach. Facilitated PCI has the potential to improve both very early and later reperfusion; ongoing trials are evaluating the benefits of this approach and the mortality benefit and safety of combination therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 07:17:37